Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Shaffer Website

Arthur L. Shaffer III, Ph.D.

Selected Publications

1)  Yang Y, Shaffer AL, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, Balasubramanian S, Mathews LA, Shinn P, Guha R, Ferrer M, Thomas C, Waldmann TA, Staudt LM.
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma.
Cancer Cell. 21: 723-37, 2012.
[Journal]
2)  Shaffer AL, Young RM, Staudt LM.
Pathogenesis of human B cell lymphomas.
Annu. Rev. Immunol. 30: 565-610, 2012.
[Journal]
3)  Valdez PA, Vithayathil PJ, Janelsins BM, Shaffer AL, Williamson PR, Datta SK.
Prostaglandin E2 suppresses antifungal immunity by inhibiting interferon regulatory factor 4 function and interleukin-17 expression in T cells.
Immunity. 36: 668-79, 2012.
[Journal]
4)  Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, Hurt EM, Shaffer AL, Kuehl WM, Staudt LM.
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.
Blood. 117: 2396-404, 2011.
[Journal]
5)  Pérez-Galán P, Mora-Jensen H, Weniger MA, Shaffer AL, Rizzatti EG, Chapman CM, Mo CC, Stennett LS, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Maric I, Dunleavy KM, Wilson WH, Staudt LM, Wiestner A.
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
Blood. 117: 542-52, 2011.
[Journal]
6)  Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM.
Oncogenically active MYD88 mutations in human lymphoma.
Nature. 470: 115-9, 2011.
[Journal]
7)  Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM.
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Nature. 463: 88-92, 2010.
[Journal]
8)  Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Möller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D, Staudt LM.
Cooperative epigenetic modulation by cancer amplicon genes.
Cancer Cell. 18: 590-605, 2010.
[Journal]
9)  Shaffer AL, Emre NC, Romesser PB, Staudt LM.
IRF4: Immunity. Malignancy! Therapy?.
Clin. Cancer Res. 15: 2954-61, 2009.
[Journal]
10)  Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM.
IRF4 addiction in multiple myeloma.
Nature. 454: 226-31, 2008.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 6/20/2012.